Stay updated with breaking news from Tim mayleben. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year . ....
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of. | March 24, 2022 ....
Esperion Therapeutics Inc. is undergoing yet another change of leadership within its C-suite. The Ann Arbor-based pharmaceutical company disclosed on Tuesday that Richard Bartram, Esperion's CFO, was stepping down effective April 8, according to a filing with the U.S. Securities and Exchange… ....
The plaintiffs in a 5-year-old lawsuit alleging securities fraud against an Ann Arbor drugmaker could get a settlement later this summer.
The class action lawsuit, filed in May 2016, alleges that Esperion Therapeutics Inc. and its CEO Tim Mayleben, made false and misleading statements to… ....
The plaintiffs in a 5-year-old lawsuit alleging securities fraud against an Ann Arbor drugmaker could get a settlement later this summer.
The class action lawsuit, filed in May 2016, alleges that Esperion Therapeutics Inc. and its CEO Tim Mayleben, made false and misleading statements to… ....